H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genocea Biosciences (GNCA – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $2.10.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 23.6% and a 49.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Genocea Biosciences is a Strong Buy with an average price target of $7.00, representing a 211.1% upside. In a report issued on October 29, Needham also assigned a Buy rating to the stock with a $7.00 price target.
Based on Genocea Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $453K and GAAP net loss of $4.56 million. In comparison, last year the company had a GAAP net loss of $7.53 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.